{"id":62742,"date":"2026-04-09T20:52:32","date_gmt":"2026-04-09T12:52:32","guid":{"rendered":"https:\/\/flcube.com\/?p=62742"},"modified":"2026-04-09T20:52:34","modified_gmt":"2026-04-09T12:52:34","slug":"haisco-pharmas-hsk42360-selected-for-nmpa-spark-program-first-braf-v600-inhibitor-for-pediatric-glioma-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62742","title":{"rendered":"Haisco Pharma&#8217;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China"},"content":{"rendered":"\n<p><strong>Haisco Pharmaceutical Group Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE:\u202f002653<\/a>) announced that its novel drug candidate <strong>HSK42360<\/strong> has been <strong>included<\/strong> in the <strong>Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK) project<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>. The designated indication is <strong>relapsed or progressive glioma carrying the BRAF V600 mutation<\/strong> in pediatric patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>CDE \/ NMPA (China)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>SPARK (Support Anti\u2011tumor drugs R&amp;D for Kids)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HSK42360 (BRAF V600 inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/progressive BRAF V600\u2011mutant pediatric glioma<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>No approved targeted therapy<\/strong> for this indication in China<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Brain\u2011penetrant small molecule inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>BRAF V600 mutation<\/strong> \u2013 Key oncogenic driver in glioma and other solid tumors<\/li>\n\n\n\n<li><strong>Molecule:<\/strong> <strong>Brain\u2011penetrant small molecule inhibitor<\/strong> designed to cross blood\u2011brain barrier<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective inhibition of mutant BRAF kinase activity, blocking MAPK\/ERK oncogenic signaling cascade<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> CNS penetration addresses unmet need in <strong>pediatric brain tumors<\/strong> where standard therapies fail<\/li>\n\n\n\n<li><strong>Broader Development:<\/strong> Also under evaluation for <strong>advanced BRAF V600\u2011mutant solid tumors<\/strong> in adult populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-context-amp-unmet-need\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Pediatric Glioma<\/strong><\/td><td>Most common CNS tumor in children<\/td><\/tr><tr><td><strong>BRAF V600 Prevalence<\/strong><\/td><td>~15\u201120% of pediatric low\u2011grade gliomas; higher in specific subtypes<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Surgery, radiation, chemotherapy \u2013 limited efficacy in relapsed cases<\/td><\/tr><tr><td><strong>Targeted Therapy Gap<\/strong><\/td><td><strong>No approved BRAF V600 inhibitor<\/strong> for pediatric glioma in China<\/td><\/tr><tr><td><strong>Prognosis<\/strong><\/td><td>Poor outcomes for relapsed\/progressive disease; urgent need for precision therapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPARK Program Benefits:<\/strong><\/li>\n\n\n\n<li><strong>Accelerated regulatory pathway<\/strong> with dedicated CDE guidance<\/li>\n\n\n\n<li><strong>Priority review<\/strong> status for pediatric oncology applications<\/li>\n\n\n\n<li><strong>Data requirements flexibility<\/strong> enabling faster development timelines<\/li>\n\n\n\n<li><strong>First\u2011Mover Position:<\/strong> HSK42360 positioned as <strong>potential first\u2011to\u2011market<\/strong> BRAF V600 therapy for pediatric glioma in China, capturing orphan drug advantages.<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Builds on Haisco&#8217;s CNS and oncology expertise; adult solid tumor program provides clinical foundation for pediatric expansion.<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Addressable market of <strong>~3,000\u20115,000 annual pediatric BRAF V600\u2011mutant glioma cases<\/strong> in China; orphan pricing supports <strong>\u00a5300\u2011500\u202fmillion<\/strong> peak revenue potential.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory pathways, clinical development timelines, and commercial expectations for HSK42360. Actual results may differ due to risks including trial failures, safety signals, competitive entry, and reimbursement uncertainties in pediatric oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,139,929],"class_list":["post-62742","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-haisco-pharmaceutical","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharma&#039;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62742\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharma&#039;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&amp;D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62742\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:52:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:52:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharma&#8217;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China\",\"datePublished\":\"2026-04-09T12:52:32+00:00\",\"dateModified\":\"2026-04-09T12:52:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Haisco Pharmaceutical\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62742#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62742\",\"name\":\"Haisco Pharma's HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-09T12:52:32+00:00\",\"dateModified\":\"2026-04-09T12:52:34+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62742\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62742#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharma&#8217;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharma's HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62742","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharma's HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China","og_description":"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.","og_url":"https:\/\/flcube.com\/?p=62742","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:52:32+00:00","article_modified_time":"2026-04-09T12:52:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62742#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62742"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharma&#8217;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China","datePublished":"2026-04-09T12:52:32+00:00","dateModified":"2026-04-09T12:52:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62742"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Haisco Pharmaceutical","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62742#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62742","url":"https:\/\/flcube.com\/?p=62742","name":"Haisco Pharma's HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-09T12:52:32+00:00","dateModified":"2026-04-09T12:52:34+00:00","description":"Haisco Pharmaceutical Group Co., Ltd (SHE:\u202f002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti\u2011tumor drugs R&D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62742#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62742"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62742#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharma&#8217;s HSK42360 Selected for NMPA SPARK Program \u2013 First BRAF V600 Inhibitor for Pediatric Glioma in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62742"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62742\/revisions"}],"predecessor-version":[{"id":62743,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62742\/revisions\/62743"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}